데어 바이오사이언스DARE 주가

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 millionFunding award milestone follows Daré's announcement last week of the initiation of its Phase 2 clinical study of DARE-HPV — representing the first time women with persistent high-risk HPV infection may have access to this pharmacologic treatment as part of a clinical trialDARE-HPV targets high-risk HPV infection, the cause of virtually all cervical cancer cases in t

Dare Biosciences Receives Second $1M Tranche Of NIH Funding

Receipt of award notice for second $1.0 million tranche of NIAID funding brings total NIH funding award for DARE-HPV to $2.0 millionFunding award milestone follows Daré's announcement last week of the initiation of its

Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

Each year, an estimated six million women in the United States acquire a high-risk HPV infection — and there are no FDA-approved treatments DARE-HPV development is backed by a $10 million U.S. government (ARPA-H)-funded contract; topline data readout expected in 2027 SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today

♻️ 재탕Daré Bioscience initiates phase 2 study of Dare-HPV

Daré Bioscience Inc: Daré Bioscience initiates phase 2 study of Dare-HPV, a novel pharmacologic treatment for persistent high-risk HPV infection with no FDA-approved therapies Daré Bioscience...

Daré Bioscience Initiates Phase 2 Clinical Study Of DARE-HPV Treatment

The Phase 2 study is a randomized, placebo-controlled, double-blind trial designed to evaluate the safety and antiviral activity of a lower and higher DARE-HPV dose compared with placebo in approximately 100 women with

♻️ 재탕[8-K] 중대 사건 — 8-K

♻️ 재탕12 Health Care Stocks Moving In Friday's Pre-Market Session

Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ...

Dare Bioscience Inc (DARE) announces key product launches and funding strategies amid capital constraints and regulatory hurdles.

[253G2] 253G2 — 253G2

♻️ 재탕Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript

Daré Bioscience, Inc. (DARE) Q1 2026 Earnings Call May 14, 2026 4:30 PM EDTCompany ParticipantsMarDee Haring-Layton - Chief Accounting OfficerSabrina...